Intetumumab

• CAT Number: I042419
• CAS Number: 725735-28-4
• Molecular Weight: 145.6 (kDa)
• Purity: ≥95%

Intetumumab (Cat No.: I042419) is a human monoclonal antibody that targets integrin αv, a protein involved in cell adhesion, migration, and survival. It was developed for potential cancer therapy, particularly in solid tumors like melanoma and non-small cell lung cancer. By blocking integrins, Intetumumab aims to inhibit tumor angiogenesis and metastasis. Although it showed promise in preclinical models, clinical trials revealed limited efficacy, and development was eventually discontinued. Nonetheless, it remains significant for understanding integrin-targeted therapeutic strategies in oncology research.

Reference

[1]. Bellone M, et, al. Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody. Int J Gynecol Cancer. 2011 Aug;21(6):1084-90.
[Content Brief]

[2]. Gonzalez-Nicolini V, et, al. Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy. Clin Cancer Res. 2016 May 15;22(10):2453-61.
[Content Brief]